Along with aiding efforts to study addicted smokers, a new drug that attaches only to areas of the brain that have been implicated in nicotine addiction may help studies of people battling other disorders such as Alzheimer’s disease and schizophrenia.
Developed by UC Irvine Transdisciplinary Tobacco Use Research Center scientists, the new drug – Nifrolidine – is a selective binding agent that identifies specific areas of the brain responsible for decision-making, learning and memory. Lead researcher Jogeshwar Mukherjee, UCI associate professor of psychiatry and human behavior, developed Nifrolidine to measure a subtype of nicotine receptors in the living brain by using an imaging technique, positron emission tomography, more commonly known as PET scans. After proving the drug’s effectiveness, Mukherjee believes the drug will have implications for other conditions, as well.
Study results appear in the January issue of the Journal of Nuclear Medicine.
“Nifrolidine is suited to provide reliable, quantitative information of these receptors and may therefore be very useful for future human brain imaging studies of nicotine addiction and other clinical conditions in which these brain regions have been implicated,” Mukherjee said.